XM does not provide services to residents of the United States of America.
U
U

UCB


News

UCB Receives U.S. FDA Approval For Bimzelx® (Bimekizumab-Bkzx)

BRIEF-UCB Receives U.S. FDA Approval For Bimzelx® (Bimekizumab-Bkzx) Nov 20 (Reuters) - Ucb SA UCB.BR : UCB RECEIVES U.S. FDA APPROVAL FOR BIMZELX® (BIMEKIZUMAB-BKZX) AS THE FIRST IL-17A AND IL-17F INHIBITOR FOR ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA Source text: ID:nPn9zTJhra Further company coverage: UCB.BR
U

UCB Receives U.S. FDA Approval For Bimzelx

BRIEF-UCB Receives U.S. FDA Approval For Bimzelx Nov 20 (Reuters) - Ucb SA UCB.BR : RECEIVES U.S. FDA APPROVAL FOR BIMZELX(BIMEKIZUMAB-BKZX) AS FIRST IL-17A AND IL-17F INHIBITOR FOR ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA APPROVAL IS SUPPORTED BY DATA FROM TWO PHASE 3 STUDIES, BE HEARD I AND BE HEARD II Source text: ID:nNDL295pXp Fu
U

UCB Presents Dapirolizumab Pegol Phase 3 Data

BRIEF-UCB Presents Dapirolizumab Pegol Phase 3 Data Nov 19 (Reuters) - Ucb SA UCB.BR : DAPIROLIZUMAB PEGOL PHASE 3 DATA SHOWS SIGNIFICANT REDUCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY DAPIROLIZUMAB PEGOL (DZP) MET ITS PRIMARY ENDPOINT Source text: ID:nGNX9FDwjP Further company coverage: UCB.BR (Gdansk Newsroom)
U

European pharma stocks slip after Trump taps RFK Jr to lead top US health agency

BUZZ-European pharma stocks slip after Trump taps RFK Jr to lead top US health agency ** Share in healthcare companies drop the most in Europe, hurt by the news that Donald Trump has selected Robert F. Kennedy Jr. , who has previously spread misinformation on vaccines, to lead the country's top health agency ** STOXX 600 Healthcare index .SXDP at -2.09% is the biggest faller among the pan-European indices ** At 1113.76 points, the sub-index is at its lowest in 7 months and is heading for its big
A
G
R
S
U

UCB Raises 2024 Guidance, Completes Sale Of Established Brands

BRIEF-UCB Raises 2024 Guidance, Completes Sale Of Established Brands Nov 5 (Reuters) - Ucb SA UCB.BR : UCB COMPLETES SALE OF ESTABLISHED BRANDS AND UPDATES 2024 FINANCIAL GUIDANCE UPDATE OF 2024 FINANCIAL GUIDANCE, PROJECTING REVENUE NEAR €6 BILLION AND AN ADJUSTED EBITDA MARGIN EXPECTED NOW WITHIN THE UPPER PART OF THE RANGE OF 23.0-24.5% SUCCES
U

UCB Presents Data On Bepranemab In Early Alzheimer's Disease In Phase 2A Study

BRIEF-UCB Presents Data On Bepranemab In Early Alzheimer's Disease In Phase 2A Study Oct 31 (Reuters) - Ucb SA UCB.BR : UCB PRESENTS ENCOURAGING DATA ON BEPRANEMAB IN EARLY ALZHEIMER’S DISEASE IN PHASE 2A STUDY AT CTAD 2024 RESULTS PROVIDE FIRST EVIDENCE OF BIOLOGICAL AND CLINICAL EFFECT OF A MID-DOMAIN TAU-TARGETING DISEASE-MODIFYING THERAPY IS
U

Clariant, M6, Ucb

EUROPE RESEARCH ROUNDUP-Clariant, M6, Ucb Oct 30 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Clariant, M6, and Ucb, on Wednesday. HIGHLIGHTS * Adidas AG ADSGn.DE : Deutsche Bank raises target price to EUR 275 from EUR 270 * Clariant AG CLN.S : JP Morgan cuts target price to CHF 14 from CHF 15 * M6 MMTP.PA : JP Morgan cuts target price to EUR 13.1 from EUR 13.7 * Nel ASA NEL.OL : Morgan Stanley cuts to underweight from equal wei
A
A
A
A
B
B
C
C
D
E
E
F
H
H
H
H
K
L
M
R
S
U
V
B
D

Glencore, Knaus Tabbert, LSE

EUROPE RESEARCH ROUNDUP- Glencore, Knaus Tabbert, LSE Oct 28 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Glencore, Knaus Tabbert and LSE, on Monday. HIGHLIGHTS * Glencore Plc GLEN.L : HSBC raises to buy from hold * Knaus Tabbert AG KTAG.DE : Jefferies cuts to hold from buy * LSE LSEG.L : RBC raises target price to 11,600p from 11,000p * Suzano SUZB3.SA : HSBC raises to buy from hold * Veolia VIE.PA : RBC initiates coverage with
A
B
D
E
E
E
E
F
G
H
H
H
I
K
R
R
R
S
S
U
V
B
E
S
Y

EMA Starts Review Of Drugs Containing Finasteride & Dutasteride After Suicidal Ideation Concerns

CORRECTED-BRIEF-EMA Starts Review Of Drugs Containing Finasteride & Dutasteride After Suicidal Ideation Concerns Corrects source of brief to European Medicines Agency, not Merck & Co Oct 4 (Reuters) - European Medicines Agency (EMA): EMA: HAS STARTED A REVIEW OF MEDICINES CONTAINING FINASTERIDE AND DUTASTERIDE FOLLOWING CONCERNS REGARDING SUICIDAL
U

UCB Announces A Study Evaluating Bimzelx Versus Skyrizi In Psoriatic Arthritis

BRIEF-UCB Announces A Study Evaluating Bimzelx Versus Skyrizi In Psoriatic Arthritis Sept 30 (Reuters) - Ucb SA UCB.BR : ANNOUNCES A HEAD-TO-HEAD STUDY EVALUATING BIMZELX[®]▼(BIMEKIZUMAB) VERSUS SKYRIZI® (RISANKIZUMAB) IN ACTIVE PSORIATIC ARTHRITIS STUDY UNDERSCORES UCB'S BELIEF IN BIMEKIZUMAB WITH TOP-LINE RESULTS EXPECTED IN 2026 Source text:
U

UCB Announces Late-Breaking 2 Year Data For Bimekizumab In HS

BRIEF-UCB Announces Late-Breaking 2 Year Data For Bimekizumab In HS Sept 27 (Reuters) - Ucb SA UCB.BR : ANNOUNCES LATE-BREAKING TWO-YEAR DATA FOR BIMZELX(BIMEKIZUMAB) IN MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA AT EADV 2024 CLINICALLY MEANINGFUL IMPROVEMENTS OBSERVED WITH BIMEKIZUMAB OVER ONE YEAR OF TREATMENT WERE MAINTAINED UP TO TWO YEARS (WE
U

Biogen rises after lupus drug meets main goal of late-stage study

BUZZ-Biogen rises after lupus drug meets main goal of late-stage study ** Shares of drugmaker Biogen BIIB.O rise 2.1% to $200 premarket ** Co and partner UCB UCB.BR say their experimental lupus treatment met the main goal of a late-stage trial ** Cos say the drug, dapirolizumab pegol, when given along with other standard of care treatments, showed
B
U

UCB Announces Positive Results From Phase 3 Study Of Dapirolizumab Pegol

BRIEF-UCB Announces Positive Results From Phase 3 Study Of Dapirolizumab Pegol Sept 24 (Reuters) - UCB UCB.BR : UCB AND BIOGEN ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 STUDY OF DAPIROLIZUMAB PEGOL IN SYSTEMIC LUPUS ERYTHEMATOSUS ARE INITIATING SECOND PHASE 3 STUDY IN 2024 PARTICIPANTS FROM PHOENYCS GO STUDY WILL CONTINUE TO BE FOLLOWED IN A L
B
U

Biogen-UCB's lupus drug meets main goal of late-stage trial

CORRECTED-Biogen-UCB's lupus drug meets main goal of late-stage trial Corrects executive's name to Meyers from Myers in paragraphs 5 and 6 By Manas Mishra Sept 24 (Reuters) - Biogen BIIB.O and Belgian partner UCB UCB.BR said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug failed an earlier mid-stage study.
A
B
G
U

UCB rises on further Bimzelx approvals in the US

BUZZ-UCB rises on further Bimzelx approvals in the US ** Shares in UCB UCB.BR rise 2.2% after the Belgian biopharmaceutical company said the U.S. FDA had approved further indications for its Bimzelx treatment ** Bimzelx gets green light for psoriatic arthritis, nonradiographic axial spondyloarthritis and axial spondyloarthritis, following similar d
U

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Asia Cement, McKesson Aug 26 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Monday: ** Asia Cement (China)'s 0743.HK shareholders have rejected its majority owner's take-private offer, it said. nL4N3KD0SV ** Drug distributor McKesson MCK.N said it would buy a controlling stake in community cancer center Florida Cancer Specialists & Research Institute's business and administrative services unit, Core
N
S
U
M

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Aug 26 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Monday: ** UCB UCB.BR , a Belgian biopharmaceutical firm, said it would sell its Chinese neurology and allergy business to Singapore-based asset management group CBC and Abu Dhabi sovereign investor Mubadala for $680 million.
N
S
U

Belgium's UCB to sell China neurology, allergy business for $680 mln

UPDATE 2-Belgium's UCB to sell China neurology, allergy business for $680 mln Acquisition includes anti-allergy medicines Zyrtec and Xyzal Deal expected to close in fourth quarter UCB to focus on innovation and partnerships Adds context in paragraph 7, advisers in final paragraph By Geert De Clercq and Yantoultra Ngui PARIS/SINGAPORE, Aug 26 (Reuters) - UCB UCB.BR , a Belgian biopharmaceutical firm, said on Monday it would sell its Chinese neurology and allergy business to Singapore-based asset
U

Mubadala Co-Invests In UCB's Mature Business In China

BRIEF-Mubadala Co-Invests In UCB's Mature Business In China Aug 26 (Reuters) - MUBADALA INVESTMENT [RIC:RIC:MUDEV.UL]: MUBADALA CO-INVESTS IN UCB'S MATURE BUSINESS IN CHINA TO REINFORCE ITS LONG-TERM COMMITMENT TO ASIAN MARKET CO IN PARTNERSHIP WITH CBC GROUP ACQUIRED 100% OWNERSHIP IN CARVE-OUT OF UCB PHARMA'S MATURE BUSINESS IN CHINA Further comp
U

Belgium's UCB sells China neurology and allergy business for $680 million

Belgium's UCB sells China neurology and allergy business for $680 million PARIS, Aug 26 (Reuters) - Belgian biopharmaceutical group UCB said in a statement it had agreed to sell its neurology and allergy business in China to Asian healthcare-dedicated asset management group CBC and Abu Dhabi-based investment company Mubadala for an amount of $680 million.
U



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.